Evidence map›Paper›PMID 40059532›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2025

Volumetric Nanodroplet-Enhanced Ultrasound Surgery Combined with Immune Checkpoint Inhibition as a Cancer Therapy Platform.

Bar Glickstein, Mike Bismuth, Roni Gattegno, Tiran Bercovici, Oz Shaul, Ramona Aronovich, Galit Horn, Anat Globerson Levin, Yi Feng, Tali Ilovitsh

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Acoustically Activatable Drug-Loaded Nanodroplets for Mechanochemical Therapy in Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Bar GlicksteinDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0009-0001-3842-6897
Mike BismuthDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
Roni GattegnoDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
Tiran BercoviciDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
Oz ShaulSchool of Electrical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
Ramona AronovichDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.
Galit HornImmunology and Advanced CAR-T Cell Therapy Laboratory, Research & Development Department, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, 6423906, Israel.
Anat Globerson LevinImmunology and Advanced CAR-T Cell Therapy Laboratory, Research & Development Department, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, 6423906, Israel.
Yi FengThe Key Laboratory of Biomedical Information Engineering of the Ministry of Education, Department of Biomedical Engineering, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, 710049, China.
Tali IlovitshDepartment of Biomedical Engineering, Tel Aviv University, Tel Aviv, 6997801, Israel.ORCID 0000-0001-6215-0299

Funding

Horizon 2020 Framework Programme 101041118Israel Science Foundation 192/22Israel Science Foundation 3450/20Marian Gertner InstituteMinistry of Science and Technology, Israel 101716National Natural Science Foundation of China 82061148015
6 · The paper itself

Abstract

Immune checkpoint inhibitors hold promise, yet their efficacy in solid tumors is limited by the complex tumor microenvironment and the lack of immune cell infiltration. This study aims to enhance immunotherapy by combining anti PD-1 checkpoint inhibition therapy with nanodroplet-mediated histotripsy. The proposed method involves systemic injection of nanodroplets, which accumulate within tumors. These nanodroplets are then activated into cavitating gas bubbles using a rotating imaging probe, followed by low-frequency ultrasound application. This process induces tumor fractionation, facilitating the shift of the tumor microenvironment from cold to hot. Tumor ablation results show extensive lesions within the cancerous tissues, demonstrating the effectiveness of the ablation treatment. The combined approach of nanodroplets, ultrasound and anti PD-1 yielded a significant reduction in tumor growth compared to control groups. Immunohistochemistry analysis reveals an increase in F4/80+ macrophages and CD8+ T cells in the treated tumor group, indicating an enhanced immune response. F4/80+ macrophages reached 21.36% ± 3.4%, while CD8+ T-cell recruitment achieved 6.76% ± 4.5%, representing a 6.8- and a 5.5-fold increase compared to the control group, respectively. This approach demonstrates the potential to overcome key barriers in solid tumor treatment by combining precise mechanical disruption with systemic immune activation.

Indexed as

Immune Checkpoint InhibitorsNanoparticlesNeoplasmsUltrasonic TherapyAnimalsCD8-Positive T-LymphocytesCell Line, TumorHumansImmunotherapyMacrophagesMiceMice, Inbred C57BLTumor MicroenvironmentImmune Checkpoint Inhibitorscancer therapycheckpoint inhibitionfocused ultrasoundhistotripsyimmunotherapymechanical ablationnanodroplets

Identifiers

PMID40059532
PMCPMC12160685

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.